European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

EVA - patient ventilation beyond limits

Objetivo

EVA - Expiratory Ventilation Assistance – , or expiration by suction, is an innovative method to mechanically ventilate patients and is a key step in ventilation towards less-invasive, tailored and improved patient care as it enables:
1. full ventilation through a thin catheter instead of a thick tube
2. low and – if needed – negative pressures in the lungs promoting blood circulation
3. controlling the expiration, reducing sheer stress, which may prevent lung injury and improve patient outcome.

The EVA technology has already been on the market for some years in its most basic form: the manual, disposable emergency ventilator Ventrain®. Since market launch in 2011, Ventrain® is now being sold by 16 distributors in over 20 countries.
Ventinova’s flagship is the “EVA device”: a fully automated ventilator based on EVA technology meeting the emerging needs of less invasive, tailored and improved patient care. First is focused on the large markets of elective surgical procedures and emergency care (€ 400 M, globally) and in 2nd generation on ICU-ventilation (€ 500 M, globally), before becoming ‘standard care’ (€ 4.6 billion, globally). The device, currently at TRL6, is still in development and CE marking is expected in Q3 2016. Next to marketing activities, such as organizing workshops and training sessions, and careful selection and support of distributors, penetration of the conservative medical market should be ensured by demonstration of better and tailored patient care using EVA ventilation in pre-clinical studies and controlled clinical trials. These are to be designed and executed in close collaboration with Key Opinion Leaders of established and world leading academic medical centers.

The described technology and products are protected by 5 patent families and design and brand registrations. The products are manufactured in The Netherlands and a dedicated catheter in Ireland. After CE marking, large non-EU markets are to be entered (e.g. USA, China, Russia).

Régimen de financiación

IA - Innovation action

Coordinador

VENTINOVA MEDICAL BV
Aportación neta de la UEn
€ 793 261,87
Dirección
MEERENAKKERPLEIN 7
5652 BJ Eindhoven
Países Bajos

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
Zuid-Nederland Noord-Brabant Zuidoost-Noord-Brabant
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 1 133 231,24

Participantes (4)